Skip to content

Clinical observation of multiple dose use of tranexamic acid in patients with rheumatoid arthritis after total knee arthroplasty

Effects of multiple dose use of tranexamic acid on blood loss and inflammatory factors after total knee arthroplasty in patients with rheumatoid arthritis

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025013
Enrollment
Unknown
Registered
2019-08-07
Start date
2019-08-08
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee arthroplasty

Interventions

group 1:Intravenous infusion of 1g of tranexamic acid at 3 hours after surgery
group 2:Intravenous infusion of 1g of tranexamic acid at 3, 6, and 12 hours after surgery

Sponsors

Guanghua Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as rheumatoid arthritis according to the "Classification of Rheumatoid Arthritis" revised by the American College of Rheumatology in 1978 and the classification of rheumatoid arthritis by the American College of Rheumatology and the European Union of Rheumatology in 2010. Kellgren-LawrenceX line is graded III or IV; 2. Aged 50-75 years; 3. Initial unilateral TKA surgery; 4. Perioperative TXA antifibrinolytic therapy; 5. Preoperative hemoglobin, The coagulation function is normal.

Exclusion criteria

Exclusion criteria: 1. Other types of arthritis (such as primary arthritis, post-traumatic osteoarthritis, gouty osteoarthritis, haemophilic osteoarthritis, and tuberculous arthritis); 2. Bilateral knee arthroplasty (RA patients); 3. Severe cardiovascular disease (such as myocardial infarction, atrial fibrillation, angina pectoris, and cardiac failure) or cerebrovascular disease (such as cerebral infarction and cerebral haemorrhage); and 4. Prolonged use of oral anticoagulant drugs (such as aspirin, warfarin, and clopidogrel).

Design outcomes

Primary

MeasureTime frame
Hemoglobin;The blood loss;transfusion rate;

Countries

China

Contacts

Public ContactXiao Lianbo

Guanghua Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai University of Traditional Chinese Medicine

xiao_lianbo@163.com+86 18621697913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026